Researchers sought to elucidate the activity and efficacy of targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy or not, which are commonly used in patients with melanoma brain metastases.
Scientific Publications
Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab
In this secondary analysis of phase 1 CA209-003 trial, researchers examined 270 patients with advanced melanoma, renal cell carcinoma (RCC), or non–small cell lung cancer (NSCLC) to determine 5-year survival associated with nivolumab treatment in these patients, as well as to identify factors related to 5-year survival.
Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study
In a prospective cohort of women in France, researchers assessed melanoma risk in relation to menopausal hormone therapy (MHT) use.
Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review
In melanoma patients, the efficacy and safety of two treatment regimens were compared: BRAF inhibition plus MEK inhibition combination therapy vs BRAF inhibition monotherapy, via this meta-analysis.